Drug Profile
BI 1026706
Alternative Names: BI-1026706Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim Pharmaceuticals
- Class Analgesics; Antirheumatics; Eye disorder therapies
- Mechanism of Action Bradykinin B1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diabetic macular oedema
- No development reported Chronic obstructive pulmonary disease; Osteoarthritis; Postoperative pain
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease in Denmark (PO, Tablet)
- 28 Sep 2021 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease in Germany (PO, Tablet)
- 28 Sep 2021 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease in Sweden (PO, Tablet)